Open AccessCost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
Author(s) -
Shuwen Yu
Publication year - 2017
Publication title -
journal of chinese pharmaceutical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.138
H-Index - 12
ISSN - 1003-1057
DOI - 10.5246/jcps.2017.06.049
Subject(s) - bevacizumab , erlotinib , medicine , oncology , lung cancer , chemotherapy , cancer , epidermal growth factor receptor
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom